| Safety and activity of anti–PD-L1 antibody in patients with advanced cancer JR Brahmer, SS Tykodi, LQM Chow, WJ Hwu, SL Topalian, P Hwu, ... New England Journal of Medicine 366 (26), 2455-2465, 2012 | 7919 | 2012 |
| Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ... New England Journal of Medicine 377 (19), 1824-1835, 2017 | 1810 | 2017 |
| Tumor and microenvironment evolution during immunotherapy with nivolumab N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba, JS Sims, FS Hodi, ... Cell 171 (4), 934-949. e16, 2017 | 1298 | 2017 |
| PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma PT Nghiem, S Bhatia, EJ Lipson, RR Kudchadkar, NJ Miller, L Annamalai, ... New England Journal of Medicine 374 (26), 2542-2552, 2016 | 1144 | 2016 |
| Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial HL Kaufman, J Russell, O Hamid, S Bhatia, P Terheyden, SP D'Angelo, ... The lancet oncology 17 (10), 1374-1385, 2016 | 1132 | 2016 |
| Treatment of metastatic melanoma: an overview S Bhatia, SS Tykodi, JA Thompson Oncology (Williston Park, NY) 23 (6), 488, 2009 | 718 | 2009 |
| Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ... Journal of the National Comprehensive Cancer Network 17 (3), 255-289, 2019 | 383 | 2019 |
| Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics KG Paulson, SY Park, NA Vandeven, K Lachance, H Thomas, ... Journal of the American Academy of Dermatology 78 (3), 457-463. e2, 2018 | 350 | 2018 |
| Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy P Nghiem, S Bhatia, EJ Lipson, WH Sharfman, RR Kudchadkar, AS Brohl, ... Journal of Clinical Oncology 37 (9), 693, 2019 | 283 | 2019 |
| Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial HL Kaufman, JS Russell, O Hamid, S Bhatia, P Terheyden, SP D’Angelo, ... Journal for immunotherapy of cancer 6, 1-7, 2018 | 279 | 2018 |
| NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020: featured updates to the NCCN guidelines JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ... Journal of the National Comprehensive Cancer Network 18 (3), 230-241, 2020 | 229 | 2020 |
| Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1 … PA Ascierto, I Melero, S Bhatia, P Bono, RE Sanborn, EJ Lipson, ... Journal of Clinical Oncology 35 (15_suppl), 9520-9520, 2017 | 226 | 2017 |
| Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma JG Iyer, A Blom, R Doumani, C Lewis, ES Tarabadkar, A Anderson, C Ma, ... Cancer medicine 5 (9), 2294-2301, 2016 | 216 | 2016 |
| Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma JA Thompson, BD Curti, BG Redman, S Bhatia, JS Weber, SS Agarwala, ... Journal of clinical oncology 26 (12), 2034-2039, 2008 | 200 | 2008 |
| Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype AG Chapuis, JA Thompson, KA Margolin, R Rodmyre, IP Lai, K Dowdy, ... Proceedings of the National Academy of Sciences 109 (12), 4592-4597, 2012 | 189 | 2012 |
| Systemic immune suppression predicts diminished merkel cell carcinoma–specific survival independent of stage KG Paulson, JG Iyer, A Blom, EM Warton, M Sokil, L Yelistratova, ... Journal of Investigative Dermatology 133 (3), 642-646, 2013 | 187 | 2013 |
| Systemic immune suppression predicts diminished merkel cell carcinoma–specific survival independent of stage KG Paulson, JG Iyer, A Blom, EM Warton, M Sokil, L Yelistratova, ... Journal of Investigative Dermatology 133 (3), 642-646, 2013 | 187 | 2013 |
| Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: survival analyses of 6908 cases from the National Cancer Data Base S Bhatia, BE Storer, JG Iyer, A Moshiri, U Parvathaneni, D Byrd, AJ Sober, ... JNCI: Journal of the National Cancer Institute 108 (9), 2016 | 181 | 2016 |
| Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma CS Grasso, J Tsoi, M Onyshchenko, G Abril-Rodriguez, ... Cancer cell 38 (4), 500-515. e3, 2020 | 173 | 2020 |
| Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced CancerSingle-Agent Utomilumab in Patients with Advanced Cancer NH Segal, AR He, R Levy, S Bhatia, MJ Pishvaian, R Cesari, Y Chen, ... Clinical Cancer Research 24 (8), 1816-1823, 2018 | 173 | 2018 |
Paul NghiemUniversity of Washington; Fred Hutchinson Cancer Research CenterVerified email at uw.edu
